Group 1: IPO Market Overview - In the past week (July 28 - August 3, 2025), seven companies submitted IPO applications in the Hong Kong market, including YunTianLiFei (688343.SH), XinWangDa (300207.SZ), and DanNuo Pharmaceutical [3][4] - Two companies passed the Hong Kong Stock Exchange hearing: TianYue Advanced (688234.SH) and YinNuo Pharmaceutical [3][4] - One new company, ZhongHui Biological (02627.HK), initiated its IPO process, with no companies successfully listed during this period [3][4] Group 2: ZhongHui Biological - ZhongHui Biological officially launched its IPO on July 31, 2025, with a global offering of 33.4426 million shares, priced between HKD 12.90 and HKD 15.50 per share [3][17] - The expected listing date on the Hong Kong Stock Exchange is August 8, 2025 [3][17] - The company has secured cornerstone investors who agreed to subscribe for shares totaling approximately HKD 102 million [17][19] Group 3: YunTianLiFei - YunTianLiFei is a leading AI company in China, focusing on the research, design, and commercialization of AI inference chips [6] - The company ranks among the top three providers of AI inference chip-related products and services in China, based on revenue statistics for 2024 [7] - For the three months ending March 31, 2025, YunTianLiFei reported revenue of RMB 264 million, a year-on-year increase of 168.2%, but incurred a net loss of RMB 85.801 million, a decrease of 37.9% year-on-year [8] Group 4: XinWangDa - XinWangDa, a global leader in lithium battery technology, aims to provide integrated solutions for green and efficient energy [8] - The company has a diverse product matrix, including energy storage systems, consumer batteries, and power batteries [8] - For the three months ending March 31, 2025, XinWangDa recorded revenue of RMB 12.289 billion, a year-on-year increase of 12.0%, and a 21.3% increase in profit attributable to shareholders [9] Group 5: DanNuo Pharmaceutical - DanNuo Pharmaceutical is a biotechnology company focused on discovering, developing, and commercializing innovative drug products for bacterial infections and related diseases [10][11] - The company has established a pipeline of seven innovative assets, with no products currently approved for commercial sale [12][14] - For the three months ending March 31, 2025, DanNuo reported a net loss of RMB 38.011 million, an increase of 36.4% year-on-year [14] Group 6: TianYue Advanced - TianYue Advanced is a leading manufacturer of wide bandgap semiconductor materials, focusing on the research and industrialization of silicon carbide substrates [15] - The company ranks among the top three global manufacturers of silicon carbide substrates based on sales revenue for 2024 [15] - For the three months ending March 31, 2025, TianYue reported revenue of RMB 408 million, a year-on-year decrease of 4.2%, and a net profit of RMB 8.518 million, a decrease of 81.5% year-on-year [16] Group 7: YinNuo Pharmaceutical - YinNuo Pharmaceutical is a science-driven biopharmaceutical company focused on providing innovative and affordable high-quality drugs for metabolic diseases [16] - The company has developed a pipeline of candidate drugs targeting diabetes and other metabolic diseases, including a core product for treating obesity and related conditions [16] - For the five months ending May 31, 2025, YinNuo reported revenue of RMB 38.144 million, with a net loss of RMB 97.875 million, an increase of 58.1% year-on-year [16]

Market Review - The Huaxia Sci-Tech AI ETF (589010) declined by 0.98% on July 30, remaining above the five-day moving average, indicating a technical digestion after previous gains [1] - The Optoelectronics sector led the decline with a drop of 7.71%, while Tianzhun Technology, Cambricon, and Star Ring Technology saw declines exceeding 3% [1] - The Robotics ETF (562500) fell by 1.44%, with a lackluster performance over the past week, suggesting potential left-side layout opportunities [1] - Dongjie Intelligent surged by 9.19%, while Zhongdali De led the decline with a drop of 9.32%, and several stocks like Dazhu Laser and Guomao shares fell over 3% [1] - Total trading volume exceeded 1.1 billion yuan, with a turnover rate of 6.91%, indicating a slight expansion in trading volume [1] Hot News - Microsoft's Q4 FY2025 earnings surpassed market expectations, with revenue reaching $76.44 billion, a year-on-year growth of 18%, marking the fastest growth in nearly three years [2] - The net profit increased from $22.04 billion in the same period last year to $27.23 billion [2] - The Intelligent Cloud segment, including Azure, reported a 26% year-on-year revenue growth to $29.9 billion [2] - Following the earnings report, Microsoft's stock surged by 8% in after-hours trading, approaching a market capitalization of $4.1 trillion [2] - Taotao Automotive and Yushu Technology signed a strategic cooperation agreement to explore new opportunities in the robotics industry [2] - Yuntian Lifa submitted a listing application to the Hong Kong Stock Exchange, focusing on AI-driven NPU chips for various application scenarios [2] Institutional Views - Dongfang Securities believes that the integration of AI features is driving the smart watch market towards higher-end products [2] - AI applications are gradually being implemented in smart watches, enhancing user interaction and health/sports monitoring capabilities [2] - In the children's smart watch sector, AI is expected to empower safety for children, indicating growth potential in high-end smart watch demand [2] Popular ETFs - The Robotics ETF (562500) is the only ETF in the market with a scale exceeding 100 billion yuan, offering the best liquidity and comprehensive coverage of the Chinese robotics industry [3] - The Huaxia Sci-Tech AI ETF (589010) captures the "singularity moment" in the AI industry with a 20% fluctuation limit and small-cap elasticity [3]